Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor el

Cancer Chemotherapy and Pharmacology

Volumn 43, Issue 1, 1999, Pages 13-18

  Ellis, A G ^a   Webster, L K ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Cremophor; Drug interaction; Paclitaxel; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; CREMOPHOR; DRUG METABOLITE; DRUG VEHICLE; ETOPOSIDE; PACLITAXEL;

ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; LIVER METABOLISM; LIVER PERFUSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BILE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCEROL; HALF-LIFE; LIVER; MALE; PACLITAXEL; RATS; RATS, SPRAGUE-DAWLEY; SURFACE-ACTIVE AGENTS;

EID: 0032913097     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050857     Document Type: Article

References (23)

1. 1. Ellis AG, Webster LW (1996) Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. Cancer Chemother Pharmacol 38: 81-87
2. 2. Fisher GA, Lum BL, Hausdorff J, Sikic BI (1996) Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer 32A: 1982-1088
3. 3. Gianni L, Kearns CM, Capri G, Vigano L, Locatelli A, Bonadonna G, Gianni A, Egorin MJ (1995) Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13: 180-190
4. 4. Gianni L, Vigano L, Locatelli A, Capri G, Giani A, Tarenzi E, Bonadonna G (1997) Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 15: 1906-1915
5. 5. Huizing MT, Sewberath Misser VH, Pieters RC, Ten Bokkel Huinink WW, Vechof CHN, Vermorken JB, Pinedo HM, Beijnen JH (1995) Taxanes. A new class of antitumour agents. Cancer Invest 13: 381-404
6. 6. Jamis-Dow C, Klecker R, Katki A, Collins J (1995) Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences. Cancer Chemother Pharmacol 36: 107-114
7. 7. Kessel D (1992) Properties of Cremophor EL micelles probed by fluorescence. Photochem Photobiol 56: 447-451
8. 8. Kongshaug M, Cheng LS, Moan J, Rimington C (1991) Interaction of Cremophor EL with human plasma. Int J Biochem 23: 473-478
9. 9. Liebmann J, Cook J, Lipschultz C, Teague D, Fisher J, Mitchell J (1994) The influence of Cremophor EL on the cell cycle effects of paclitaxel in human tumor cell lines. Cancer Chemother Pharmacol 33: 331-339
10. 10. Monsarrat B, Mariel E, Cros S, Gares M, Guenard D, Gueritte-Voelelein F, Wright M (1990) Taxol metabolism: isolation and identification of three major metabolites of Taxol in rat bile. Drug Metab Dispos 18: 895-901
11. 11. Monsarrat B, Alvinerie P, Wright M, Dubois J, Gueritte-Voelelein F, Guenard D, Donehower R, Rowinsky E (1993) Hepatic metabolism and biliary excretion of taxol in rats and humans Monogr Natl Cancer Inst 15: 39-46
12. 12. Ohtsu T, Sasaki Y, Tamura T, Miyata Y, Nakanomyo H, Nishiwaki Y, Saijo N (1995) Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-h infusion versus a 24-h infusion. Clin Cancer Res 1: 599-606
13. 13. Rischin D, Millward M, Webster L, Tinnelly K, Toner G, Bishop (1994) Phase I trial of Cremophor EL and doxorubicin in patients with advanced cancer. Anticancer Drugs 5 [suppl 1]: 43-44
14. 14. Rischin D, Webster LK, Millward MJ, Linahan BM, Toner GC, Woollett AM, Morton CG, Bishop JF (1996) Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-h infusions of paclitaxel. J Natl Cancer Inst 88: 1297-1301
15. 15. Schuurhuis GJ, Broxterman HJ, Pinedo HM, Heijningen THM van, Kalken CK van, Vermorken JB, Spoelstra EC, Lankelma J (1990) The polyoxyethylene caster oil Cremophor EL modifies multidrug resistance. Br J Cancer 62: 591-594
16. 16. Sonnichsen D, Relling M (1994) Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet 27: 256-269
17. 17. Sparreboom A, Tellingen O van, Nooijen WJ, Beijnen JH (1996) Tissue distribution, metabolism and excretion of paclitaxel in mice. Anticancer Drugs 7: 78-86
18. 18. Sparreboom A, Tellingen O van, Nooijen WJ, Beijnen JH (1996) Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 56: 2112-2115
19. 19. Sykes E, Woodburn K, Decker D, Kessel D (1994) Effects of Cremophor EL on distribution of Taxol to serum lipoproteins. Br J Cancer 70: 401-404
20. 20. Webster L, Linsenmeyer M, Millward M, Morton C, Bishop J, Woodcock D (1993) Measurement of Cremophor EL following Taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistance phenotype. J Natl Cancer Inst 85: 1685-1690
21. 21. Webster LK, Cosson EJ, Millward MJ, Stokes KH (1996) Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. Br J Cancer 73(4): 522-524
22. 22. Webster LK, Woodcock DM, Rischin D, Millward MJ (1997) Cremophor pharmacological activity of an "inert" solubiliser. J Oncol Pharm Pract 3: 186-192
23. 23. Woodcock DM, Jefferson S, Linsenmeyer ME, Crowther PJ, Chojnowski GM, Williams B, Bertoncello I (1990) Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res 50: 4199-4203